IL17A and psoriasis: As IL-17A is a registered therapeutic target in psoriasis, PsA, and AS, gaining novel knowledge on how Th17-derived cytokines drive joint damage could not only advance our understanding of disease mechanisms, but also help identifying potential therapeutic targets which can be used in combination with existing therapies to improve patient outcomes [19].